Our Partners

Advancing pharmaceutical innovation through collaborative synergy

Partnerships are at the heart of OEP’s mission to bring patients innovative, high-quality products.

We don’t just help develop and sell products. We create synergy. By focusing on building relationships, and maintaining nimble, customer-centric operations, we produce an end result greater than the sum of its parts.

Read our partnership profiles below to discover how an alliance with OEP drives mutual growth.

 

 

  • IN-LICENSING
  • CO-DEVELOPMENT
  • OUT-LICENSING
  • Cel-Sci
  • chiesi
  • Debiopharm-1
  • Untitled design (12)
  • Pierre Fabre-1
  • Plethora
  • Recordati
  • Second Sight
  • Supernus
  • SYNTHON
  • New Teva logo
  • Untitled design (10)
  • Untitled design (4)
  • kissei 5
  • nanocarrier
  • Untitled design (2)
  • summit
  • Untitled design (7)
  • Untitled design (8)
  • logo
  • PAI
  • teva logo official
  • Tide

Partnership Profiles

Out-licensing of Vancomycin capsules with PAI 

Out-licensing of Vancomycin capsules with PAI

OEP’s ANDA portfolio provides high-quality medications at an affordable price to patients. With our commercial partner PAI, we launched Vancomycin hydrochloride capsules, a commonly used antibiotic, into the U.S. market.

In-licensing of Multikine® cancer drug with CEL-SCI 

In-licensing of Multikine® cancer drug with CEL-SCI

A pioneer in cancer immunotherapy drugs, CEL-SCI has an exclusive licensing agreement with OEP for Multikine®, CEL-SCI’s lead investigational therapy. OEP invested in CEL-SCI, funded a portion of Multikine’s nine-year Phase III clinical trial, and obtained licensing rights to distribute Multikine in nine countries. The global Phase 3 study has ended and is in the data analysis stage. It is believed to be the largest head and neck cancer clinical study ever conducted, as well as the first to use immunotherapy ahead of surgery.

Co-development of 505(b)(2) ADHD Drug with DURECT 

Co-development of 505(b)(2) ADHD Drug with DURECT

In 2009, DURECT granted OEP the development and commercialization rights to ORADUR-Methylphenidate ER Capsule (Methydur Sustained Released Capsules), its lead ORADUR-ADHD program, in 14 Asian and South Pacific countries. Together, OEP and DURECT developed a lead formulation based on clinical trial research. OEP oversaw phase III clinical trials in Taiwan, handles manufacturing, and has received, or is pursuing regulatory approvals in 14 countries, including Australia and New Zealand.



In-licensing of CNS Drug with Supernus Pharmaceuticals  

In-licensing of CNS Drug with Supernus Pharmaceuticals

OEP partnered with Supernus Pharmaceuticals to launch Trokendi XR®, a CNS drug that helps prevent migraines, in 7 Asian countries.

Hear From Our Partners

“We congratulate OEP on the approval and recent commercial launch of Methydur, which will offer an alternative treatment for patients suffering from ADHD in Taiwan. We are pleased to see this first marketing approval for a product utilizing the ORADUR technology." 

By James E. Brown, President and CEO of DURECT Corporation  

“OEP has been a valued partner in CEL-SCI’s mission to help patients beat cancer by developing innovative immunotherapies. OEP has been meticulous in their clinical trial management of Multikine in Taiwan, and we are pleased to be able to leverage their extensive commercialization network in Asia.”.

By Geert R. Kersten, Director and CEO, CEL-SCI

“As a leader in high-quality generic pharmaceuticals for the North American market, PAI is delighted to enhance our consumer offerings with OEP’s Vancomycin product.”

By Kurt Orlofski, CEO, Pharmaceutical Associates, Inc.